Tarsus Pharmaceuticals (TARS) Competitors $49.12 +0.40 (+0.82%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$49.04 -0.07 (-0.15%) As of 04/15/2025 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TARS vs. ROIV, LNTH, TGTX, RVMD, BBIO, LEGN, BPMC, SRPT, TLX, and AXSMShould you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Roivant Sciences (ROIV), Lantheus (LNTH), TG Therapeutics (TGTX), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), Blueprint Medicines (BPMC), Sarepta Therapeutics (SRPT), Telix Pharmaceuticals Limited American Depositary Shares (TLX), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Tarsus Pharmaceuticals vs. Roivant Sciences Lantheus TG Therapeutics Revolution Medicines BridgeBio Pharma Legend Biotech Blueprint Medicines Sarepta Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Axsome Therapeutics Roivant Sciences (NASDAQ:ROIV) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, community ranking and risk. Is ROIV or TARS more profitable? Tarsus Pharmaceuticals has a net margin of -103.64% compared to Roivant Sciences' net margin of -119.54%. Roivant Sciences' return on equity of -14.05% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Roivant Sciences-119.54% -14.05% -12.81% Tarsus Pharmaceuticals -103.64%-55.86%-39.28% Do insiders and institutionals have more ownership in ROIV or TARS? 64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 7.9% of Roivant Sciences shares are owned by insiders. Comparatively, 8.3% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, ROIV or TARS? Roivant Sciences has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Does the media refer more to ROIV or TARS? In the previous week, Roivant Sciences had 1 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 9 mentions for Roivant Sciences and 8 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.27 beat Roivant Sciences' score of 1.26 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Tarsus Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor ROIV or TARS? Roivant Sciences received 2 more outperform votes than Tarsus Pharmaceuticals when rated by MarketBeat users. Likewise, 78.26% of users gave Roivant Sciences an outperform vote while only 68.42% of users gave Tarsus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRoivant SciencesOutperform Votes5478.26% Underperform Votes1521.74% Tarsus PharmaceuticalsOutperform Votes5268.42% Underperform Votes2431.58% Which has preferable valuation and earnings, ROIV or TARS? Roivant Sciences has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Roivant Sciences is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoivant Sciences$122.59M58.56$4.35B-$0.15-67.07Tarsus Pharmaceuticals$182.95M10.30-$135.89M-$3.10-15.85 Do analysts recommend ROIV or TARS? Roivant Sciences presently has a consensus price target of $17.50, suggesting a potential upside of 73.96%. Tarsus Pharmaceuticals has a consensus price target of $63.67, suggesting a potential upside of 29.61%. Given Roivant Sciences' higher probable upside, equities research analysts clearly believe Roivant Sciences is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryRoivant Sciences beats Tarsus Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Remove Ads Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARS vs. The Competition Export to ExcelMetricTarsus PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.89B$2.90B$5.33B$7.57BDividend YieldN/A1.91%5.11%4.33%P/E Ratio-12.8931.0021.7317.81Price / Sales10.30441.15379.1494.58Price / CashN/A168.6838.1534.64Price / Book8.263.476.464.00Net Income-$135.89M-$72.06M$3.20B$247.23M7 Day Performance10.06%9.33%6.54%7.26%1 Month Performance2.14%-16.97%-8.55%-6.26%1 Year Performance40.58%-29.10%10.33%-0.18% Tarsus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARSTarsus Pharmaceuticals2.9585 of 5 stars$49.12+0.8%$63.67+29.6%+40.6%$1.89B$182.95M-12.8950Positive NewsROIVRoivant Sciences2.6317 of 5 stars$9.26-2.1%$17.50+89.0%-7.2%$6.61B$122.59M-61.73860Positive NewsGap DownHigh Trading VolumeLNTHLantheus4.3411 of 5 stars$95.45+5.0%$129.43+35.6%+70.6%$6.54B$1.53B15.88700Positive NewsTGTXTG Therapeutics3.3148 of 5 stars$37.25-0.3%$40.67+9.2%+177.4%$5.85B$329.00M-372.46290Positive NewsRVMDRevolution Medicines3.8147 of 5 stars$31.40+0.3%$65.23+107.7%+2.2%$5.84B$742,000.00-8.75250Positive NewsHigh Trading VolumeBBIOBridgeBio Pharma4.5716 of 5 stars$30.67-2.2%$52.64+71.6%+32.9%$5.83B$221.90M-10.76400Analyst ForecastGap DownLEGNLegend Biotech2.409 of 5 stars$30.25-5.5%$79.00+161.2%-34.8%$5.56B$627.24M-31.841,070Positive NewsGap UpBPMCBlueprint Medicines2.6341 of 5 stars$80.20-1.8%$124.95+55.8%-4.4%$5.13B$508.82M-74.26640Positive NewsHigh Trading VolumeSRPTSarepta Therapeutics4.6725 of 5 stars$52.40-3.7%$163.18+211.4%-54.0%$5.08B$1.90B41.92840Short Interest ↑Gap DownHigh Trading VolumeTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$14.25+4.7%$22.00+54.4%N/A$4.81B$783.21M0.00N/AAXSMAxsome Therapeutics4.5823 of 5 stars$98.50-0.4%$169.80+72.4%+52.2%$4.80B$385.69M-16.44380Analyst Revision Remove Ads Related Companies and Tools Related Companies Roivant Sciences Alternatives Lantheus Alternatives TG Therapeutics Alternatives Revolution Medicines Alternatives BridgeBio Pharma Alternatives Legend Biotech Alternatives Blueprint Medicines Alternatives Sarepta Therapeutics Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Axsome Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TARS) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump’s betrayal exposed Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TARS Stock Free TARS Stock Alerts